ArticleThe American journal of pathology2004
CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 148 citations in OpenAlex.
- Cytologic Detection of Metastatic Immature Teratomas in Two Young Patients With Unique Presentations.Diagnostic cytopathology · 2026Article
- Calcifying nested stromal-epithelial tumor of the liver: Report of two cases revealing novel WT1 mutation and distinct epigenetic features.Virchows Archiv : an international journal of pathology · 2026Article
- Identification and Validation of a Prognostic Model Based on Tumour Necrosis Factor-Related mRNAs for Kidney Renal Clear Cell Carcinoma.Journal of cellular and molecular medicine · 2025Article
- A phenome-wide association study of uterine fibroids reveals a marked burden of comorbidities.Communications medicine · 2025Article
- Impacts of low birthweight on kidney development and intergenerational growth of the offspring.iScience · 2024Article
- Single-cell multiomics reveals ENL mutation perturbs kidney developmental trajectory by rewiring gene regulatory landscape.Nature communications · 2024Article
- Insights into Personalized Care Strategies for Wilms Tumor: A Narrative Literature Review.Biomedicines · 2024Review
- A GAD1 inhibitor suppresses osteosarcoma growth through the Wnt/β-catenin signaling pathway.Heliyon · 2024Article
- Cancer predisposition signaling in Beckwith-Wiedemann Syndrome drives Wilms tumor development.British journal of cancer · 2024Article
- Altered binding affinity of SIX1-Q177R correlates with enhanced WNT5A and WNT pathway effector expression in Wilms tumor.Disease models & mechanisms · 2023Article
- Hypercapnia alters stroma-derived Wnt production to limit β-catenin signaling and proliferation in AT2 cells.JCI insight · 2023Article
- The Long Noncoding RNA Cytoskeleton Regulator RNA (CYTOR)/miRNA-24-3p Axis Facilitates Nasopharyngeal Carcinoma Progression by Modulating GAD1 Expression.Journal of oncology · 2023Article
- Article
- Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.Journal for immunotherapy of cancer · 2022Article
- Identifying tumor immunity-associated molecular features in liver hepatocellular carcinoma by multi-omics analysis.Frontiers in molecular biosciences · 2022Article
- KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis.British journal of pharmacology · 2021Article
- GAD1 expression and its methylation as indicators of malignant behavior in thymic epithelial tumors.Oncology letters · 2021Article
- Article
- Constitutive activation of CTNNB1 results in a loss of spermatogonial stem cell activity in mice.PloS one · 2021Article
- Inferring clonal composition from multiple tumor biopsies.NPJ systems biology and applications · 2020Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gain-of-function mutations in exon 3 of beta-catenin (CTNNB1) are specific for Wilms' tumors that have lost WT1, but 50% of WT1-mutant cases lack such "hot spot" mutations. To ask whether stabilization of beta-catenin might be essential after WT1 loss, and to identify downstream target genes, we compared expression profiles in WT1-mutant versus WT1 wild-type Wilms' tumors. Supervised and nonsupervised hierarchical clustering of the expression data separated these two classes of Wilms' tumor. The WT1-mutant tumors overexpressed genes encoding myogenic and other transcription factors (MOX2, LBX1, SIM2), signaling molecules (TGFB2, FST, BMP2A), extracellular Wnt inhibitors (WIF1, SFRP4), and known beta-catenin/TCF targets (FST, CSPG2, CMYC). Beta-Catenin/TCF target genes were overexpressed in the WT1-mutant tumors even in the absence of CTNNB1 exon 3 mutations, and complete sequencing revealed gain-of-function mutations elsewhere in the CTNNB1 gene in some of these tumors, increasing the overall mutation frequency to 75%. Lastly, we identified and validated a novel direct beta-catenin target gene, GAD1, among the WT1-mutant signature genes. These data highlight two molecular classes of Wilms' tumor, and indicate strong selection for stabilization of beta-catenin in the WT1-mutant class. Beta-Catenin stabilization can initiate tumorigenesis in other systems, and this mechanism is likely critical in tumor formation after loss of WT1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.